Page last updated: 2024-12-11

ly 341495

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 341495: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10713043
SCHEMBL ID24606222
MeSH IDM0295542
PubMed CID9819927
CHEMBL ID432038
CHEBI ID93224
SCHEMBL ID481153
MeSH IDM0295542

Synonyms (46)

Synonym
ly 341495
CS-0010412
(rac)-ly341495
F83709
HY-70059A
SCHEMBL24606222
CHEMBL432038 ,
201943-63-7
HY-70059
HMS3267B15
gtpl1399
ly-341,495
[3h]ly341495
[3h]alpha-9'-xantheylmethyl-2-(carboxycyclopropyl)glycine
gtpl1378
ly341495
NCGC00025041-02
2-[(1s,2s)-2-carboxycyclopropyl]-3-(9h-xanthen-9-yl)-d-alanine
z99 ,
2-[1-amino-1-carboxy-2-(9h-xanthen-9-yl)-ethyl]-cyclopropanecarboxylic acid(ly341495)
(1s,2s)-2-[1-amino-1-carboxy-2-(9h-xanthen-9-yl)-ethyl]-cyclopropanecarboxylic acid
bdbm50062522
(1s,2s)-2-[(1s)-1-amino-1-carboxy-2-(9h-xanthen-9-yl)ethyl]cyclopropanecarboxylic acid
(1s,2s)-2-[(s)-1-amino-1-carboxy-2-(9h-xanthen-9-yl)-ethyl]-cyclopropanecarboxylic acid
(s)-2-[(s)-1-amino-1-carboxy-2-(9h-xanthen-9-yl)-ethyl]-cyclopropanecarboxylic acid
(1s,2s)-2-((s)-1-amino-1-carboxy-2-(9h-xanthen-9-yl)ethyl)cyclopropanecarboxylic acid
BCP9000885
CS-0343
(2s)-2-amino-2-[(1s,2s)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid
BRD-K69763916-001-01-7
J-501015
SCHEMBL481153
AKOS024456466
sr-01000597370
SR-01000597370-1
(1s,2s)-2-[(1s)-1-amino-1-carboxy-2-(9h-xanthen-9-yl)ethyl]cyclopropane-1-carboxylic acid
CHEBI:93224
2(s)-amino-2-[2(s)-carboxy-1(s)-cyclopropyl]-3-(9h-xanthen-9-yl)propionic acid
DTXSID50942264
Q6460424
(1s,2s)-2-[(1s)-1-amino-1-carboxy-2-(9h-xanthen-9-yl)ethyl]-1-cyclopropanecarboxylic acid
9h-xanthene-9-propanoic acid, alpha-amino-alpha-[(1s,2s)-2-carboxycyclopropyl]-, (alphas)-
MS-25484
A926529
(alphas)-alpha-amino-alpha-[(1s,2s)-2-carboxycyclopropyl]-9h-xanthene-9-propanoic acid
(2s)-2-amino-2-[(1s,2s)-2-carboxycy cloprop-1-yl]-3-(xanth-9-yl) propanoic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Dual orthosteric agonists of metabotropic glutamate 2 (mGlu2) and mGlu3 receptors are being developed as novel antipsychotic agents devoid of the adverse effects of conventional antipsychotics."( Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mGlu2 an
Battaglia, G; Britton, TC; Bruno, V; Cannella, M; Caraci, F; Copani, A; Drago, F; Giuffrida, ML; Heinz, BA; Merlo, S; Molinaro, G; Nicoletti, F; Nisenbaum, ES; Riozzi, B; Sortino, MA; Traficante, A; Wang, X, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
"0]hexane-2,6-dicarboxylic acid (-)-11be (MGS0039) was a highly selective and potent group II mGluR antagonist with the best pharmacokinetic profile."( Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
Chaki, S; Itoh, M; Nakamura, M; Nakazato, A; Ohta, H; Sakagami, K; Yasuhara, A; Yoshikawa, R, 2004
)
0.32
"49 nM) for mGluR2 as 1 but had a superior pharmacokinetic profile."( Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.
Chaki, S; Kawakita, Y; Nakazato, A; Saito, A; Sakagami, K; Taguchi, T; Yasuhara, A; Yoshikawa, R, 2008
)
0.35

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study we examined whether administration of N-acetyl-aspartyl-glutamate (NAAG) in combination with mild hypothermia could improve striatal neuroprotection in the endothelin-1 rat model."( Neuroprotective effect of N-acetyl-aspartyl-glutamate in combination with mild hypothermia in the endothelin-1 rat model of focal cerebral ischaemia.
Ebinger, G; Hachimi-Idrissi, S; Michotte, Y; Sarre, S; Van Hemelrijck, A, 2005
)
0.33

Bioavailability

ExcerptReferenceRelevance
" Neither LY379268 nor LY341495 influenced the central bioavailability and the local half-life of MPTP, as shown by measurements of the toxin and its active metabolite, MPP(+), in the striatum."( Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Battaglia, G; Biagioni, F; Bruno, V; Busceti, CL; Fornai, F; Nicoletti, F; Paparelli, A; Pontarelli, F; Ruggieri, S, 2003
)
0.32
"The aim of this study was to assess the efficacy of a structurally novel, potent, selective mGlu2/3 receptor agonist with improved bioavailability (LY404039) in animal models predictive of antipsychotic and anxiolytic efficacy."( In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.
Griffey, KI; Johnson, BG; Knitowski, KM; McKinzie, DL; Monn, JA; Perry, KW; Rorick-Kehn, LM; Salhoff, CR; Schoepp, DD; Tizzano, JP; Witkin, JM, 2007
)
0.34
" However, the poor oral bioavailability of NAAG and 2-PMPA limits their practical use in humans."( Oral administration of the NAALADase inhibitor GPI-5693 attenuates cocaine-induced reinstatement of drug-seeking behavior in rats.
Ashby, CR; Gardner, EL; Li, J; Peng, XQ; Slusher, BS; Thomas, A; Wozniak, K; Xi, ZX, 2010
)
0.36

Dosage Studied

ExcerptRelevanceReference
" However, LY487379 markedly potentiated glutamate-stimulated [35S]GTPgammaS binding in a concentration-dependent manner at hmGluR2, shifting the glutamate dose-response curve leftward by 3-fold and increasing the maximum levels of [35S]GTPgammaS stimulation."( Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2.
Bain, G; Bristow, LJ; Chavez-Noriega, LE; Daggett, LP; Jachec, C; Morales, S; Pinkerton, AB; Rao, SP; Rowe, BA; Schaffhauser, H; Varney, MA; Vernier, JM; Yin, R, 2003
)
0.32
" Different groups of rats received bilateral microinjections of LY37 into BA at two dosage ranges (3."( Effects of microinjections of Group II metabotropic glutamate agents into the amygdala on sleep.
Dong, E; Sanford, LD; Wellman, LL; Yang, L, 2012
)
0.38
" Further characterization of the dose-response effects of the compounds on quisqualate induced [Ca2+]i mobilization showed that although the magnitude of phenylglycine inhibition was reduced for both mGluR subtypes compared to those observed for stimulation of PI hydrolysis (except for 4C3HPG on mGluR1 alpha), similar differences in the relative potencies of the phenylglycines between mGluR1 alpha (IC50s: 40 +/- 10 microM for 4C3HPG: 300-1000 microM for 4CPG and M4CPG) and mGluR5a (IC50s: > 1000 microM) were evident."( Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects on mGluR1 alpha and mGluR5a subtypes.
Burnett, JP; Kingston, AE; Lodge, D; Mayne, NG, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
xanthenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metabotropic glutamate receptor 8Homo sapiens (human)IC50 (µMol)0.17000.00510.06030.1700AID107419
Metabotropic glutamate receptor 8Homo sapiens (human)Ki0.17000.06103.68859.5000AID107274
NADH-cytochrome b5 reductase 3 Homo sapiens (human)IC50 (µMol)8.20008.20008.20008.2000AID107417
Metabotropic glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)8.99000.00020.58878.9900AID241911
Metabotropic glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.11160.02320.11160.2000AID107411; AID241912
Metabotropic glutamate receptor 2Rattus norvegicus (Norway rat)Ki0.00310.00310.12650.4760AID239366
Metabotropic glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)0.01680.01420.01680.0210AID107413; AID221664; AID241913; AID705391
Metabotropic glutamate receptor 3Rattus norvegicus (Norway rat)Ki0.00300.00300.13400.4760AID239367
Metabotropic glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)2.65000.01280.89192.6500AID241914
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)IC50 (µMol)11.40000.00000.52627.9700AID241915
Metabotropic glutamate receptor 6Rattus norvegicus (Norway rat)IC50 (µMol)1.14001.14001.14001.1400AID241916
Metabotropic glutamate receptor 7Rattus norvegicus (Norway rat)Ki0.11000.11000.11000.1100AID239368
Metabotropic glutamate receptor 5Homo sapiens (human)IC50 (µMol)8.20000.00050.439410.0000AID107417
Metabotropic glutamate receptor 5Homo sapiens (human)Ki8.20000.00050.54638.2000AID107059
Metabotropic glutamate receptor 1Homo sapiens (human)IC50 (µMol)7.80000.00052.01408.8000AID107410
Metabotropic glutamate receptor 1Homo sapiens (human)Ki6.80000.00033.536310.0000AID108489
Metabotropic glutamate receptor 2Homo sapiens (human)IC50 (µMol)0.04690.00290.46624.3000AID108816; AID1714557; AID1714566; AID222324; AID328245; AID705391
Metabotropic glutamate receptor 2Homo sapiens (human)Ki0.01260.00270.71586.4000AID108833; AID1714563
Metabotropic glutamate receptor 7Homo sapiens (human)IC50 (µMol)0.99000.99000.99000.9900AID107418
Metabotropic glutamate receptor 7Homo sapiens (human)Ki0.99000.99000.99000.9900AID107261
Metabotropic glutamate receptor 3Homo sapiens (human)IC50 (µMol)0.00860.00280.46271.5000AID109157; AID1714558; AID1714567; AID705389
Metabotropic glutamate receptor 3Homo sapiens (human)Ki0.00770.00130.61549.0000AID109164; AID1714564
Metabotropic glutamate receptor 4Homo sapiens (human)IC50 (µMol)22.00000.00510.00510.0051AID107415
Metabotropic glutamate receptor 4Homo sapiens (human)Ki22.00000.16001.15672.4000AID109341
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metabotropic glutamate receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.20004.494610.0000AID240178
Metabotropic glutamate receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.00061.42627.7000AID240179
Metabotropic glutamate receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.00211.89099.0000AID240180
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.00151.653710.0000AID240181
Metabotropic glutamate receptor 6Rattus norvegicus (Norway rat)EC50 (µMol)100.00000.05502.40307.6000AID240182
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 8Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 8Homo sapiens (human)
visual perceptionMetabotropic glutamate receptor 8Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 8Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 8Homo sapiens (human)
cholesterol biosynthetic processNADH-cytochrome b5 reductase 3 Homo sapiens (human)
nitric oxide biosynthetic processNADH-cytochrome b5 reductase 3 Homo sapiens (human)
blood circulationNADH-cytochrome b5 reductase 3 Homo sapiens (human)
desensitization of G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of DNA-templated transcriptionMetabotropic glutamate receptor 5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
phospholipase C-activating G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 5Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 5Homo sapiens (human)
learning or memoryMetabotropic glutamate receptor 5Homo sapiens (human)
learningMetabotropic glutamate receptor 5Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of long-term neuronal synaptic plasticityMetabotropic glutamate receptor 5Homo sapiens (human)
synapse organizationMetabotropic glutamate receptor 5Homo sapiens (human)
positive regulation of calcium-mediated signalingMetabotropic glutamate receptor 5Homo sapiens (human)
cognitionMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 5Homo sapiens (human)
cellular response to amyloid-betaMetabotropic glutamate receptor 5Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 5Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 1Homo sapiens (human)
locomotory behaviorMetabotropic glutamate receptor 1Homo sapiens (human)
sensory perception of painMetabotropic glutamate receptor 1Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of sensory perception of painMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 1Homo sapiens (human)
cellular response to electrical stimulusMetabotropic glutamate receptor 1Homo sapiens (human)
L-glutamate import across plasma membraneMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 1Homo sapiens (human)
negative regulation of adenylate cyclase activityMetabotropic glutamate receptor 2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 2Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 2Homo sapiens (human)
gene expressionMetabotropic glutamate receptor 2Homo sapiens (human)
glutamate secretionMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of glutamate secretionMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of dopamine secretionMetabotropic glutamate receptor 2Homo sapiens (human)
behavioral response to nicotineMetabotropic glutamate receptor 2Homo sapiens (human)
response to cocaineMetabotropic glutamate receptor 2Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionMetabotropic glutamate receptor 2Homo sapiens (human)
long-term synaptic depressionMetabotropic glutamate receptor 2Homo sapiens (human)
intracellular glutamate homeostasisMetabotropic glutamate receptor 2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of response to drugMetabotropic glutamate receptor 2Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 2Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 2Homo sapiens (human)
behavioral fear responseMetabotropic glutamate receptor 7Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 7Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 7Homo sapiens (human)
sensory perception of soundMetabotropic glutamate receptor 7Homo sapiens (human)
negative regulation of glutamate secretionMetabotropic glutamate receptor 7Homo sapiens (human)
axon developmentMetabotropic glutamate receptor 7Homo sapiens (human)
glycosylationMetabotropic glutamate receptor 7Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 7Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 7Homo sapiens (human)
negative regulation of adenylate cyclase activityMetabotropic glutamate receptor 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 3Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 3Homo sapiens (human)
gene expressionMetabotropic glutamate receptor 3Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMetabotropic glutamate receptor 3Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 3Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 4Homo sapiens (human)
neurotransmitter secretionMetabotropic glutamate receptor 4Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of neuron apoptotic processMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 4Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMetabotropic glutamate receptor 8Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 8Homo sapiens (human)
group III metabotropic glutamate receptor activityMetabotropic glutamate receptor 8Homo sapiens (human)
nitrite reductase (NO-forming) activityNADH-cytochrome b5 reductase 3 Homo sapiens (human)
cytochrome-b5 reductase activity, acting on NAD(P)HNADH-cytochrome b5 reductase 3 Homo sapiens (human)
protein bindingNADH-cytochrome b5 reductase 3 Homo sapiens (human)
AMP bindingNADH-cytochrome b5 reductase 3 Homo sapiens (human)
ADP bindingNADH-cytochrome b5 reductase 3 Homo sapiens (human)
NAD bindingNADH-cytochrome b5 reductase 3 Homo sapiens (human)
FAD bindingNADH-cytochrome b5 reductase 3 Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 5Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
protein tyrosine kinase activator activityMetabotropic glutamate receptor 5Homo sapiens (human)
A2A adenosine receptor bindingMetabotropic glutamate receptor 5Homo sapiens (human)
identical protein bindingMetabotropic glutamate receptor 5Homo sapiens (human)
protein tyrosine kinase bindingMetabotropic glutamate receptor 5Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 5Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled receptor activity involved in regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 5Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 1Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 1Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 1Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 1Homo sapiens (human)
neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentrationMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor activity involved in regulation of postsynaptic membrane potentialMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 2Homo sapiens (human)
calcium channel regulator activityMetabotropic glutamate receptor 2Homo sapiens (human)
protein bindingMetabotropic glutamate receptor 2Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 2Homo sapiens (human)
scaffold protein bindingMetabotropic glutamate receptor 2Homo sapiens (human)
group II metabotropic glutamate receptor activityMetabotropic glutamate receptor 2Homo sapiens (human)
group III metabotropic glutamate receptor activityMetabotropic glutamate receptor 7Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 7Homo sapiens (human)
adenylate cyclase inhibitor activityMetabotropic glutamate receptor 7Homo sapiens (human)
protein dimerization activityMetabotropic glutamate receptor 7Homo sapiens (human)
serine bindingMetabotropic glutamate receptor 7Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 3Homo sapiens (human)
calcium channel regulator activityMetabotropic glutamate receptor 3Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 3Homo sapiens (human)
scaffold protein bindingMetabotropic glutamate receptor 3Homo sapiens (human)
group II metabotropic glutamate receptor activityMetabotropic glutamate receptor 3Homo sapiens (human)
G protein-coupled receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (33)

Processvia Protein(s)Taxonomy
plasma membraneMetabotropic glutamate receptor 8Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 8Homo sapiens (human)
endoplasmic reticulum membraneNADH-cytochrome b5 reductase 3 Homo sapiens (human)
extracellular regionNADH-cytochrome b5 reductase 3 Homo sapiens (human)
cytoplasmNADH-cytochrome b5 reductase 3 Homo sapiens (human)
mitochondrionNADH-cytochrome b5 reductase 3 Homo sapiens (human)
mitochondrial outer membraneNADH-cytochrome b5 reductase 3 Homo sapiens (human)
endoplasmic reticulumNADH-cytochrome b5 reductase 3 Homo sapiens (human)
endoplasmic reticulum membraneNADH-cytochrome b5 reductase 3 Homo sapiens (human)
lipid dropletNADH-cytochrome b5 reductase 3 Homo sapiens (human)
membraneNADH-cytochrome b5 reductase 3 Homo sapiens (human)
mitochondrial membraneNADH-cytochrome b5 reductase 3 Homo sapiens (human)
azurophil granule lumenNADH-cytochrome b5 reductase 3 Homo sapiens (human)
hemoglobin complexNADH-cytochrome b5 reductase 3 Homo sapiens (human)
nitric-oxide synthase complexNADH-cytochrome b5 reductase 3 Homo sapiens (human)
mitochondrionNADH-cytochrome b5 reductase 3 Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneMetabotropic glutamate receptor 4Rattus norvegicus (Norway rat)
dendriteMetabotropic glutamate receptor 5Homo sapiens (human)
cytoplasmMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 5Homo sapiens (human)
dendritic spineMetabotropic glutamate receptor 5Homo sapiens (human)
dendritic shaftMetabotropic glutamate receptor 5Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 5Homo sapiens (human)
Schaffer collateral - CA1 synapseMetabotropic glutamate receptor 5Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 5Homo sapiens (human)
postsynaptic density membraneMetabotropic glutamate receptor 5Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 5Homo sapiens (human)
nucleusMetabotropic glutamate receptor 1Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 1Homo sapiens (human)
dendriteMetabotropic glutamate receptor 1Homo sapiens (human)
Schaffer collateral - CA1 synapseMetabotropic glutamate receptor 1Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor dimeric complexMetabotropic glutamate receptor 1Homo sapiens (human)
G protein-coupled receptor homodimeric complexMetabotropic glutamate receptor 1Homo sapiens (human)
postsynaptic density membraneMetabotropic glutamate receptor 1Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 1Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 2Homo sapiens (human)
axonMetabotropic glutamate receptor 2Homo sapiens (human)
dendriteMetabotropic glutamate receptor 2Homo sapiens (human)
presynaptic membraneMetabotropic glutamate receptor 2Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 2Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 2Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 2Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 7Homo sapiens (human)
cell cortexMetabotropic glutamate receptor 7Homo sapiens (human)
membraneMetabotropic glutamate receptor 7Homo sapiens (human)
axonMetabotropic glutamate receptor 7Homo sapiens (human)
dendriteMetabotropic glutamate receptor 7Homo sapiens (human)
asymmetric synapseMetabotropic glutamate receptor 7Homo sapiens (human)
dendritic shaftMetabotropic glutamate receptor 7Homo sapiens (human)
postsynaptic membraneMetabotropic glutamate receptor 7Homo sapiens (human)
presynaptic active zoneMetabotropic glutamate receptor 7Homo sapiens (human)
receptor complexMetabotropic glutamate receptor 7Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 7Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 3Homo sapiens (human)
postsynaptic densityMetabotropic glutamate receptor 3Homo sapiens (human)
axonMetabotropic glutamate receptor 3Homo sapiens (human)
presynaptic membraneMetabotropic glutamate receptor 3Homo sapiens (human)
dendritic spineMetabotropic glutamate receptor 3Homo sapiens (human)
postsynaptic membraneMetabotropic glutamate receptor 3Homo sapiens (human)
astrocyte projectionMetabotropic glutamate receptor 3Homo sapiens (human)
glutamatergic synapseMetabotropic glutamate receptor 3Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 3Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
cytoplasmic vesicleMetabotropic glutamate receptor 4Homo sapiens (human)
presynapseMetabotropic glutamate receptor 4Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (147)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID26187Half-life in rat brain when administered perorally at a dose of 100 mg/kg; Not calculated1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID705389Antagonist activity at human mGLUR3 expressed in RGT cells assessed as inhibition of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced inhibition of forskolin stimulated cyclic-AMP2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo.
AID21460Plasma concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21466Plasma concentration after 2 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID241916Concentration required to inhibit metabotropic glutamate receptor 6 activity of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID222324Antagonistic activity against stimulation of GTP (gamma) 35 S binding by glutamate in membranes from CHO cells expressing human mGluR22001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Design, synthesis and preliminary evaluation of novel 3'-substituted carboxycyclopropylglycines as antagonists at group 2 metabotropic glutamate receptors.
AID10496Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15469Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID107417Antagonistic activity against metabotropic glutamate receptor 5 (mGluR5) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID109164Agonist potency against cloned Metabotropic glutamate receptor 3 (mGluR-3).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID13896Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID705391Antagonist activity at human mGLUR2 expressed in RGT cells assessed as inhibition of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced inhibition of forskolin stimulated cyclic-AMP2012Bioorganic & medicinal chemistry letters, Mar-01, Volume: 22, Issue:5
Radiosynthesis of PET radiotracer as a prodrug for imaging group II metabotropic glutamate receptors in vivo.
AID13899Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15324Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID239368Binding affinity towards metabotropic glutamate receptor 7 of rat expressed in CHO cells was determined by using [3H]MGS-00082004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID16227Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID239367Binding affinity towards metabotropic glutamate receptor 3 of rat expressed in CHO cells was determined by using [3H]MGS-00082004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID15465Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID13897Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21463Plasma concentration after 1 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID240178Effective concentration for agonistic activity towards metabotropic glutamate receptor 1 of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID15323Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15322Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID13894Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID26402Half-life in rat plasma when administered perorally at at a dose of 100 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID108833Antagonist potency against cloned Metabotropic glutamate receptor 22000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID1362498Agonist activity at Gi-coupled mGluR2 (unknown origin) expressed in CHO cells assessed as increase in cAMP accumulation after 1 hr by glosensor based luciferase reporter gene assay relative to control2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
Isoxazolo[3,4-d]pyridazinones positively modulate the metabotropic glutamate subtypes 2 and 4.
AID107261Agonist potency against cloned Metabotropic glutamate receptor 7 (mGluR-7).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID241915Concentration required to inhibit metabotropic glutamate receptor 5 activity of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID107274Agonist potency against cloned Metabotropic glutamate receptor 8 (mGluR-8).2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID20759Time of maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15330Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20754Time of maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20757Time of maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10498Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10499Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID13898Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20761Time of maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID328248Half life in Sprague-Dawley rat at 10 mg/kg, po2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.
AID108489Agonist potency against cloned human metabotropic glutamate receptor 12000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID328249AUC (0 to infinity) in Sprague-Dawley rat at 10 mg/kg, po2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.
AID241914Concentration required to inhibit metabotropic glutamate receptor 4 activity of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID21456Plasma concentration after 0.5 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1714558Antagonist activity at human recombinant mGlu3 receptor stably expressed in golden hamster AV12 cells co-expressing rat EAAT1 assessed as reduction in DCG IV-induced inhibition of forskolin-stimulated cAMP accumulation preincubated for 20 mins followed by2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
AID15327Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15329Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID107410Antagonistic activity against metabotropic glutamate receptor 1 (mGluR1) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID75023Binding affinity for Group II Metabotropic glutamate receptor was measured using [3H]glutamate in rat forebrain membranes1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1714563Displacement of [3H]-LY459477 from recombinant human mGlu2 receptor expressed in hamster AV12 cell membranes co-expressing rat EAAT1 incubated for 90 mins by top count scintillation method2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
AID239366Binding affinity towards metabotropic glutamate receptor 2 of rat expressed in CHO cells was determined by using [3H]MGS-00082004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID221664Compound was evaluated for the inhibition of binding of [3H]glutamate against rat recombinant mGluR3 receptors expressed in HEK293 cells2001Bioorganic & medicinal chemistry letters, Dec-17, Volume: 11, Issue:24
Design, synthesis and preliminary evaluation of novel 3'-substituted carboxycyclopropylglycines as antagonists at group 2 metabotropic glutamate receptors.
AID26401Half-life in rat plasma when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID241911Concentration required to inhibit metabotropic glutamate receptor 1 activity of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID16229Bioavailability in rat (dose 10 mg/kg p.o.)1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20758Time of maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21472Plasma concentration after 6 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID109341Agonist potency against cloned human Metabotropic glutamate receptor 4 (mGluR-4)2000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID10489Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID107415Antagonistic activity against metabotropic glutamate receptor 4 (mGluR4) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID10487Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15466Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID26185Half-life in rat brain when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21462Plasma concentration after 1 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20755Time of maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID241913Concentration required to inhibit metabotropic glutamate receptor 3 activity of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID328247Cmax in Sprague-Dawley rat at 10 mg/kg, po2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.
AID21467Plasma concentration after 2 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1714566Antagonist activity at human recombinant mGlu2 receptor stably expressed in golden hamster AV12 cell membrane co-expressing Galpha15 assessed as assessed as reduction in glutamate-induced calcium influx incubated for 90 to 120 min by Fluo-4-AM dye based F2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
AID21461Plasma concentration after 1 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID13892Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID241912Concentration required to inhibit metabotropic glutamate receptor 2 activity of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID21468Plasma concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID26186Half-life in rat brain when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21457Plasma concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10488Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID328245Displacement of [3H]-MGS0008 from mGluR2 expressed in CHO cells2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.
AID10493Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID328246Tmax in Sprague-Dawley rat at 10 mg/kg, po2008Bioorganic & medicinal chemistry, Apr-15, Volume: 16, Issue:8
Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist.
AID15887Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15326Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID107059Agonist potency against cloned metabotropic glutamate receptor 52000Journal of medicinal chemistry, Jul-13, Volume: 43, Issue:14
Ligands for glutamate receptors: design and therapeutic prospects.
AID240180Effective concentration for agonistic activity towards metabotropic glutamate receptor 3 of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID240179Effective concentration for agonistic activity towards metabotropic glutamate receptor 2 of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID21459Plasma concentration after 0.5 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20760Time of maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1714564Displacement of [3H]-LY459477 from recombinant human mGlu3 receptor expressed in hamster AV12 cell membranes co-expressing rat EAAT1 incubated for 90 mins by top count scintillation method2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
AID15886Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10495Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID240182Effective concentration for agonistic activity towards metabotropic glutamate receptor 6 of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID10491Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID26188Half-life in rat brain when administered perorally at a dose of 10 mg/kg; Not calculated1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10490Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21458Plasma concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15467Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10494Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10492Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1714557Antagonist activity at human recombinant mGlu2 receptor stably expressed in golden hamster AV12 cells co-expressing rat EAAT1 assessed as reduction in DCG IV-induced inhibition of forskolin-stimulated cAMP accumulation preincubated for 20 mins followed by2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
AID1714567Antagonist activity at human recombinant mGlu3 stably expressed in golden hamster AV12 cell membrane co-expressing Galpha15 assessed as assessed as reduction in glutamate-induced calcium influx incubated for 90 to 120 min by Fluo-4-AM dye based FLIPR assa2016Journal of medicinal chemistry, 12-22, Volume: 59, Issue:24
Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.
AID13893Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID20756Time of maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21470Plasma concentration after 4 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID22430Volume of distribution in rat plasma when administered intraperitoneally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID13895Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21464Plasma concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15325Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID107418Antagonistic activity against metabotropic glutamate receptor 7 (mGluR7) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID10500Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21465Plasma concentration after 2 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID240181Effective concentration for agonistic activity towards metabotropic glutamate receptor 5 of rat expressed in CHO cells2004Journal of medicinal chemistry, Aug-26, Volume: 47, Issue:18
Synthesis, in vitro pharmacology, structure-activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists.
AID107419Antagonistic activity against metabotropic glutamate receptor 8 (mGluR8) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID21454Plasma concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15471Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21455Plasma concentration after 0.25 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID109157Effect on 1S,3R-ACPD-induced inhibition of forskolin stimulated cyclic-AMP in RGT cells expressing human Metabotropic glutamate receptor 31998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID22431Volume of distribution in rat plasma when administered intravenously at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15463Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10497Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID16228Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg;
1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15462Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID26403Half-life in rat plasma when administered perorally at at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15468Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21471Plasma concentration after 4 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15464Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21473Plasma concentration after 6 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10486Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1362500Agonist activity at Gi-coupled mGluR4 (unknown origin) expressed in CHO cells assessed as increase in cAMP accumulation after 1 hr by glosensor based luciferase reporter gene assay relative to control2018Bioorganic & medicinal chemistry, 09-15, Volume: 26, Issue:17
Isoxazolo[3,4-d]pyridazinones positively modulate the metabotropic glutamate subtypes 2 and 4.
AID107413Antagonistic activity against metabotropic glutamate receptor 3 (mGluR3) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID15321Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID21469Plasma concentration after 4 hr at a dose of 10 mg/kg when administered intravenously1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID15470Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID196750Antagonistic activity was evaluated by using ACPD sensitive [3H]-glutamate binding assay in rat forebrain membranes1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID15328Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID107411Antagonistic activity against metabotropic glutamate receptor 2 (mGluR2) was evaluated1998Bioorganic & medicinal chemistry letters, Oct-20, Volume: 8, Issue:20
2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors.
AID26190Half-life in rat plasma when administered intraperitoneally at at a dose of 10 mg/kg1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID108816Effect on 1S,3R-ACPD-induced inhibition of forskolin stimulated cyclic-AMP in RGT cells expressing human Metabotropic glutamate receptor 21998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID10485Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours1998Journal of medicinal chemistry, Jan-29, Volume: 41, Issue:3
2-substituted (2SR)-2-amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability.
AID1346287Rat mGlu2 receptor (Metabotropic glutamate receptors)2000Neuropharmacology, Jul-24, Volume: 39, Issue:10
Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors.
AID1346268Human mGlu1 receptor (Metabotropic glutamate receptors)1998Neuropharmacology, , Volume: 37, Issue:1
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
AID1346269Human mGlu5 receptor (Metabotropic glutamate receptors)1998Neuropharmacology, , Volume: 37, Issue:1
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
AID1346282Human mGlu8 receptor (Metabotropic glutamate receptors)1998Neuropharmacology, , Volume: 37, Issue:1
LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
AID1346287Rat mGlu2 receptor (Metabotropic glutamate receptors)1998British journal of pharmacology, Feb, Volume: 123, Issue:3
Characterization of [3H]-(2S,2'R,3'R)-2-(2',3'-dicarboxy-cyclopropyl)glycine ([3H]-DCG IV) binding to metabotropic mGlu2 receptor-transfected cell membranes.
AID1346271Human mGlu2 receptor (Metabotropic glutamate receptors)1999Neuropharmacology, Oct, Volume: 38, Issue:10
[3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells.
AID1346263Human mGlu7 receptor (Metabotropic glutamate receptors)2000Naunyn-Schmiedeberg's archives of pharmacology, Dec, Volume: 362, Issue:6
Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
AID1346285Human mGlu4 receptor (Metabotropic glutamate receptors)1995Neuropharmacology, Aug, Volume: 34, Issue:8
Pharmacological analysis of 4-carboxyphenylglycine derivatives: comparison of effects on mGluR1 alpha and mGluR5a subtypes.
AID1346272Human mGlu6 receptor (Metabotropic glutamate receptors)2000Naunyn-Schmiedeberg's archives of pharmacology, Dec, Volume: 362, Issue:6
Binding of [3H](2S,1'S,2'S)-2-(9-xanthylmethyl)-2-(2'-carboxycyclopropyl) glycine ([3H]LY341495) to cell membranes expressing recombinant human group III metabotropic glutamate receptor subtypes.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (257)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (3.89)18.2507
2000's131 (50.97)29.6817
2010's106 (41.25)24.3611
2020's10 (3.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.46 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (5.88%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other247 (100.00%)84.16%
Other16 (94.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]